Vendor: Marketplace supplier
Product metadata will be available once the catalog entry is complete.
Formulations: - Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg - Oral > Solid > dosage form: 200 mg; 500 mg; 1 g; 100 mg Indications: - Squamous cell carcinoma of oropharynx - Chronic myeloid leukaemia, not elsewhere classified - Other specified sickle cell disorders or other haemoglobinopathies Source: EML workbook import
Formulations: - Oral > Solid: 50 mg tablet Oral > Liquid: 20 mg per mL Indications: - Unspecified malignant neoplasms of ill-defined or unspecified sites - Lymphoid leukaemia, not elsewhere classified - Acute myeloid leukaemia with recurrent genetic abnormalities - Langerhans cell histiocytosis Source: EML workbook import
Formulations: - Parenteral > General injections > IV: 50 mg in vial powder for injection Oral > Solid: 2 mg Indications: - Plasma cell myeloma Source: EML workbook import
Formulations: - Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial Indications: - Malignant neoplasm metastasis in large intestine - Malignant neoplasms of kidney, except renal pelvis - Rhabdomyosarcoma primary site Source: EML workbook import
Formulations: - Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection Indications: - Other specified malignant neoplasms of the ovary - Germ cell tumour of testis - Ewing sarcoma of bone and articular cartilage of unspecified sites - Osteosarcoma of bone and articular cartilage of unspecified sites - Rhabdomyosarcoma primary site - Unspecified malignant neoplasms of ill-defined or unspecified sites - Burkitt lymphoma including Burkitt leukaemia - Malignant neoplasms of kidney, except renal pelvis - Anaplastic large cell lymphoma, ALK-negative - Anaplastic large cell lymphoma, ALK-positive Source: EML workbook import
Formulations: - Parenteral > General injections > IV: 50 mg per mL in 5 mL ampoule Parenteral > General injections > IV: 50 mg per mL in vial - Local > Topical > Ointment: 5% Indications: - Unspecified malignant neoplasms of ill-defined or unspecified sites - Malignant neoplasms of nasopharynx - Malignant neoplasm metastasis in large intestine - Malignant neoplasms of breast - Malignant neoplasms of rectum - Malignant neoplasms of colon - Plantar warts Source: EML workbook import
Ready to amplify your rewards? Drop your email and we'll be in touch soon.
